Middle East And Africa Epigenetics Diagnostic Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2021 –2028 |
 Tamanho do mercado (ano base ) | USD 120.27 Million |
 Tamanho do mercado ( Ano de previsão) | USD 237.10 Million |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado de diagnóstico epigenético do Médio Oriente e África, por produto (reagentes, kits, instrumentos e consumíveis, ferramentas e enzimas de bioinformática), tecnologia (metilação do ADN, metilação das histonas, estruturas da cromatina, acetilação das histonas, grande modificação do RNA não codificante e microRNA), tipo de terapêutica (inibidores da histona desacetilase (HDAC), inibidores da DNA metiltransferase (DNMT) e outros), aplicação (oncologia, doenças cardiovasculares, doenças metabólicas, imunologia, doenças inflamatórias, doenças infeciosas e outras), utilizador final (institutos académicos e de investigação, farmacêuticos e empresas de biotecnologia, organizações de investigação contratual (CROs) e outras), canal de distribuição (licitação direta e vendas a retalho), país (África do Sul, Arábia Saudita, Emirados Árabes Unidos , Egito, Kuwait, Israel e resto do Médio Oriente e África) Tendências da indústria e Previsão para 2028.
Análise de Mercado e Insights: Mercado de Diagnóstico Epigenético no Médio Oriente e África
Espera-se que o mercado de diagnóstico epigenético do Médio Oriente e África ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,3% no período de previsão de 2021 a 2028 e prevê-se que atinja os 237,10 milhões de dólares até 2028, contra os 120,27 milhões de dólares em 2020. A elevada prevalência de doenças crónicas e o desenvolvimento tecnológico serão provavelmente os principais impulsionadores que impulsionam a procura do mercado no período de previsão.
O diagnóstico epigenético é o estudo da genética, das variações dos traços celulares e físicos e da biologia do desenvolvimento provocada pelo meio exterior. Isto, por sua vez, afeta os genes e a capacidade celular de ler genes sem ser afetado por alterações no genótipo. As alterações epigenéticas resultam em alterações no fenótipo do organismo, e não no genótipo, a sequência subjacente de ADN e ARN permanece inalterada. As alterações epigenéticas são essenciais para o desenvolvimento, pois são dinâmicas e alteram-se em relação ao meio ambiente.
As expressões genéticas do organismo são afetadas pela epigenética, o que a torna o campo mais importante da biologia molecular e da genética do desenvolvimento. Organizações, como o National Center Institute, o National Institute of Health e o International Human Epigenome Consortium, estão a financiar e a apoiar atividades de investigação e desenvolvimento relacionadas com o campo da epigenética. A epigenética também é utilizada para tratar uma variedade de doenças crónicas, como o cancro, doenças metabólicas e outras.
O relatório do mercado de diagnóstico epigenético do Médio Oriente e África fornece detalhes da quota de mercado, novos desenvolvimentos e impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações do mercado, aprovações de produtos , decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado, contacte-nos para obter um Analyst Brief. A nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir a meta desejada.
Âmbito e dimensão do mercado de diagnóstico de epigenética no Médio Oriente e África
O mercado de diagnóstico epigenético do Médio Oriente e África está categorizado em seis segmentos notáveis que se baseiam no produto, tecnologia, tipo de terapia, aplicação, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no produto, o mercado de diagnóstico epigenético do Médio Oriente e de África está segmentado em reagentes, kits, instrumentos e consumíveis, ferramentas de bioinformática e enzimas. Em 2021, prevê-se que o segmento dos reagentes domine o mercado, uma vez que os reagentes são utilizados em diversos campos, incluindo investigação, diagnóstico, biociências e educação.
- Com base na tecnologia, o mercado de diagnóstico epigenético do Médio Oriente e de África está segmentado em metilação de ADN, metilação de histonas, estruturas de cromatina, acetilação de histonas, grande RNA não codificante e modificação de microRNAs. Em 2021, prevê-se que o segmento da metilação do ADN domine o mercado, uma vez que a tecnologia de metilação do ADN está a ser utilizada numa variedade de diagnósticos epigenéticos.
- Com base no tipo de terapêutica, o mercado de diagnóstico epigenético do Médio Oriente e África está segmentado em inibidores da histona desacetilase (HDAC), inibidores da DNA metiltransferase (DNMT), entre outros. Em 2021, prevê-se que o segmento dos inibidores da histona desacetilase (HDAC) domine o mercado, uma vez que desempenha um papel importante em diversos processos biológicos, como a proliferação, progressão e diferenciação do ciclo celular.
- Com base na aplicação, o mercado de diagnóstico epigenético do Médio Oriente e África está segmentado em oncologia, doenças cardiovasculares, doenças metabólicas, imunologia, doenças inflamatórias, entre outras. Em 2021, prevê-se que o segmento da oncologia domine o mercado devido à elevada prevalência de cancro no Médio Oriente e na região africana.
- Com base no utilizador final, o mercado de diagnóstico epigenético do Médio Oriente e de África está segmentado em institutos académicos e de investigação, empresas farmacêuticas e de biotecnologia, organizações de investigação por contrato (CROs), entre outros. Em 2021, espera-se que o segmento dos institutos académicos e de investigação domine o mercado devido ao aumento da investigação de eficácia da epigenética.
- Com base no canal de distribuição, o mercado de diagnóstico epigenético do Médio Oriente e África está segmentado em concurso direto e vendas a retalho. Em 2021, prevê-se que o segmento do concurso direto domine o mercado devido à escalada das atividades de marketing relacionadas com a epigenética e a melhoria do serviço ao cliente nos países desenvolvidos e em desenvolvimento.
Análise ao nível do país do mercado de diagnóstico de epigenética no Médio Oriente e África
O mercado de diagnóstico epigenético do Médio Oriente e África é analisado, e são fornecidas informações sobre o tamanho do mercado por país, produto, tecnologia, tipo de terapia, aplicação, utilizador final e canal de distribuição.
Os países abrangidos no relatório de mercado de diagnóstico epigenético do Médio Oriente e África são a África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Kuwait, Israel e Resto do Médio Oriente e África.
Prevê-se que a África do Sul domine o mercado, devido à elevada prevalência de doenças crónicas.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e disponibilidade de marcas do Médio Oriente e de África e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, o impacto dos canais de vendas são considerados ao mesmo tempo que fornecem uma análise de previsão dos dados do país.
A presença de tecnologia avançada e as iniciativas estratégicas tomadas pelos players estão a criar novas oportunidades no Médio Oriente e em África Mercado de Diagnóstico Epigenético
O mercado de diagnóstico epigenético do Médio Oriente e África também fornece análises de mercado detalhadas para o crescimento de cada país num determinado setor com vendas de produtos, o impacto do avanço no mercado e as mudanças nos cenários regulamentares com o seu apoio ao mercado de diagnóstico epigenético . Os dados estão disponíveis para o período histórico de 2010 a 2019.
Cenário competitivo e análise da quota de mercado do diagnóstico de epigenética no Médio Oriente e África
O panorama competitivo do mercado de diagnóstico epigenético do Médio Oriente e África fornece detalhes do concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto, e amplitude, domínio de aplicação, curva de segurança tecnológica. Os dados fornecidos acima estão apenas relacionados com o foco da empresa relacionado com o mercado de diagnóstico epigenético.
Algumas das principais empresas que fornecem diagnóstico epigenético são a PerkinElmer Inc., F. Hoffman-La Roche Ltd, Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc. ., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., GlaxoSmithKline plc., MDxHealth e Abcam plc, entre outros. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
As iniciativas estratégicas dos intervenientes no mercado e os novos avanços tecnológicos para o diagnóstico epigenético estão a colmatar a lacuna para uma variedade de tratamentos.
Por exemplo,
- Em abril de 2020, o Epi proColon da Epigenomics AG, que é apenas um teste sanguíneo aprovado pela FDA para o rastreio do cancro colorretal (CRC), foi incluído nas Diretrizes CRC da National Comprehensive Cancer Network (NCCN) de 2020. Isto ajudou a empresa no crescimento da receita através das vendas.
A colaboração, as joint ventures e outras estratégias do player de mercado estão a potenciar o mercado da empresa no mercado de diagnóstico epigenético, o que também oferece o benefício para a organização melhorar a sua oferta para o mercado de diagnóstico epigenético.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
5 REGULATIONS: MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSITC MARKET
5.1 UNITED STATES
5.1.1 ROLE OF FDA
5.1.2 ROLE OF CDC AND HCFA
5.2 EUROPEAN UNION
5.3 FRANCE
5.4 AUSTRALIA
5.5 SOUTH KOREA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CANCER
6.1.2 INCREASE IN MIDDLE EAST & AFRICA GERIATRIC POPULATION
6.1.3 RISE IN RESEARCH & DEVELOPMENT (R&D) ACTIVITIES IN THE FIELD OF EPIGENETICS
6.1.4 PRESENCE OF ADVANCED TECHNOLOGIES TO IMPROVE DIAGNOSTIC EFFICIENCY
6.1.5 IMPROVING HEALTHCARE FACILITIES
6.2 RESTRAINTS
6.2.1 INADEQUACY IN IDENTIFICATION AND VALIDATION OF BIOMARKERS
6.2.2 HIGH COST OF EPIGENETICS DIAGNOSTIC EQUIPMENT
6.3 OPPORTUNITIES
6.3.1 WIDE RANGE OF APPLICATION
6.3.2 PROMOTER METHYLATION IN DIFFERENT TYPES OF CANCER
6.3.3 EMERGING MARKETS
6.3.4 INCREASING HEALTHCARE EXPENDITURE
6.3.5 RISING PER CAPITA INCOME
6.4 CHALLENGES
6.4.1 ESCALATING PRODUCT RECALL
6.4.2 SHORTAGE OF SKILLED PERSONNEL
6.4.3 EMERGENCE OF COVID-19
6.4.4 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID 19
7.5 CONCLUSION:
8 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT
8.1 OVERVIEW
8.2 REAGENTS
8.2.1 ANTIBODIES
8.2.2 BUFFERS
8.2.3 HISTONES
8.2.4 MAGNETIC BEADS
8.2.5 PRIMERS
8.2.6 OTHERS
8.3 KITS
8.3.1 CHIP SEQUENCING KIT
8.3.2 WHOLE GENOMIC AMPLIFICATION KIT
8.3.3 BISULFITE CONVERSION KIT
8.3.4 5-HMC & 5-MC ANALYSIS KITS
8.3.5 RNA SEQUENCING KIT
8.3.6 OTHERS
8.4 INSTRUMENTS & CONSUMABLES
8.4.1 NEXT-GENERATION SEQUENCERS
8.4.2 QPCR
8.4.3 MASS SPECTROMETERS
8.4.4 SONICATORS
8.4.5 OTHERS
8.5 BIOINFORMATICS TOOLS
8.6 ENZYMES
8.6.1 DNA-MODIFYING ENZYMES
8.6.2 PROTEIN-MODIFYING ENZYMES
8.6.3 RNA-MODIFYING ENZYMES
8.6.4 OTHERS
9 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 DNA METHYLATION
9.2.1 REAGENTS
9.2.2 KITS
9.2.3 INSTRUMENTS & CONSUMABLES
9.2.4 ENZYMES
9.3 HISTONE METHYLATION
9.3.1 REAGENTS
9.3.2 KITS
9.3.3 INSTRUMENTS & CONSUMABLES
9.3.4 ENZYMES
9.4 HISTONE ACETYLATION
9.4.1 REAGENTS
9.4.2 KITS
9.4.3 INSTRUMENTS & CONSUMABLES
9.4.4 ENZYMES
9.5 LARGE NON-CODING RNA
9.5.1 REAGENTS
9.5.2 KITS
9.5.3 INSTRUMENTS & CONSUMABLES
9.5.4 ENZYMES
9.6 MICRORNA MODIFICATION
9.6.1 REAGENTS
9.6.2 KITS
9.6.3 INSTRUMENTS & CONSUMABLES
9.6.4 ENZYMES
9.7 CHROMATIN STRUCTURES
9.7.1 REAGENTS
9.7.2 KITS
9.7.3 INSTRUMENTS & CONSUMABLES
9.7.4 ENZYMES
10 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY
10.1 OVERVIEW
10.2 HISTONE DEACETYLASE (HDAC) INHIBITORS
10.3 DNA METHYLTRANSFERASE (DNMT) INHIBITORS
10.4 OTHERS
11 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.2.1 SOLID TUMORS
11.2.2 LIQUID TUMORS
11.3 CARDIOVASCULAR DISEASES
11.4 METABOLIC DISEASES
11.4.1 METABOLIC SYNDROME
11.4.2 TYPE 2 DIABETES (T2D)
11.4.3 OTHERS
11.5 IMMUNOLOGY
11.6 INFLAMMATORY DISEASES
11.7 INFECTIOUS DISEASES
11.8 OTHERS
12 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER
12.1 OVERVIEW
12.2 ACADEMIC AND RESEARCH INSTITUTES
12.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
12.4 CONTRACT RESEARCH ORGANIZATIONS (CROS)
12.5 OTHERS
13 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
14 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY REGION
14.1 MIDDLE EAST & AFRICA
14.1.1 SOUTH AFRICA
14.1.2 SAUDI ARABIA
14.1.3 UAE
14.1.4 EGYPT
14.1.5 ISRAEL
14.1.6 REST OF MIDDLE EAST & AFRICA
15 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 ILLUMINA, INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 THERMO FISHER SCIENTIFIC INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 MERCK KGAA
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 BIO-RAD LABORATORIES, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 F. HOFFMANN-LA ROCHE LTD
17.5.1 COMPANY SNAPSHOT
17.5.2 RECENT FINANCIALS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 AGILENT TECHNOLOGIES, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PERKINELMER INC
17.7.1 COMPANY SNAPSHOT
17.7.2 RECENT FINANCIALS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 QIAGEN
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENTS
17.9 ABCAM PLC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 ACTIVEMOTIF
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 BLUESTAR GENOMICS INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENTS
17.12 CAMBRIDGE EPIGENETIX (CEGX)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENT
17.13 DATAR CANCER GENETICS
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENTS
17.14 DIAGENODE
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENTS
17.15 ECLIPSE BIOINNOVATIONS
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENZO LIFE SCIENCES, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 EPICYPHER
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENTS
17.18 EPIGENOMICS AG
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 EPIGENTEK GROUP INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENTS
17.2 EPIZYME, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 GLAXOSMITHKLINE PLC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MDXHEALTH
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 MNEMO
17.23.1 COMPANY SNAPSHOT
17.23.2 PRODUCT PORTFOLIO
17.23.3 RECENT DEVELOPMENT
17.24 NEW ENGLAND BIOLABS
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
17.25.1 COMPANY SNAPSHOT
17.25.2 RECENT FINANCIALS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENTS
17.26 PROMEGA CORPORATION
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 REACTION BIOLOGY
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SALARIUS PHARMACEUTICALS, INC.
17.28.1 COMPANY SNAPSHOT
17.28.2 RECENT FINANCIALS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENTS
17.29 ZYMO RESEARCH CORPORATION
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Lista de Tabela
TABLE 1 HEALTH CARE FACILITIES
TABLE 2 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)
TABLE 3 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA REAGENTS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA KITS IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA BIOINFORMATICS TOOLS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA ENZYMES IN EPIGENETICS DIAGNOSTIC MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA DNA METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA HISTONE DEACETYLASE (HDAC) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA DNA METHYLTRANSFERASE (DNMT) INHIBITORS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA ONCOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA IMMUNOLOGY IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA INFLAMMATORY DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH INSTITUTES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA CONTRACT RESEARCH ORGANIZATIONS (CROS) IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA OTHERS IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA DIRECT TENDER IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA RETAIL SALES IN EPIGENETICS DIAGNOSTIC MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 77 SOUTH AFRICA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 79 SOUTH AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 80 SOUTH AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 SOUTH AFRICA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 82 SOUTH AFRICA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 83 SOUTH AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 96 SAUDI ARABIA CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 99 SAUDI ARABIA ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 100 SAUDI ARABIA METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 101 SAUDI ARABIA EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 SAUDI ARABIA EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 103 UAE EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 104 UAE REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 105 UAE KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 106 UAE INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 107 UAE ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 108 UAE EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 109 UAE DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 110 UAE HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 111 UAE HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 112 UAE LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 113 UAE MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 114 UAE CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 115 UAE EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 116 UAE EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 117 UAE ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 118 UAE METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 119 UAE EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 120 UAE EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 121 EGYPT EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 122 EGYPT REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 123 EGYPT KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 124 EGYPT INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 125 EGYPT ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 126 EGYPT EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 127 EGYPT DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 128 EGYPT HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 129 EGYPT HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 130 EGYPT LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 131 EGYPT MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 132 EGYPT CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 133 EGYPT EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 134 EGYPT EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 136 EGYPT METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 137 EGYPT EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 138 EGYPT EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 139 ISRAEL EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 140 ISRAEL REAGENTS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 141 ISRAEL KITS IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 142 ISRAEL INSTRUMENTS & CONSUMABLES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 143 ISRAEL ENZYMES IN EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 144 ISRAEL EPIGENETICS DIAGNOSTIC MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 145 ISRAEL DNA METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 146 ISRAEL HISTONE METHYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 147 ISRAEL HISTONE ACETYLATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 148 ISRAEL LARGE NON-CODING RNA IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 149 ISRAEL MICRORNA MODIFICATION IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 150 ISRAEL CHROMATIN STRUCTURES IN EPIGENETICS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019-2028 (USD MILLION)
TABLE 151 ISRAEL EPIGENETICS DIAGNOSTIC MARKET, BY TYPE OF THERAPY, 2019-2028 (USD MILLION)
TABLE 152 ISRAEL EPIGENETICS DIAGNOSTIC MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 153 ISRAEL ONCOLOGY IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 154 ISRAEL METABOLIC DISEASES IN EPIGENETICS DIAGNOSTICS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 155 ISRAEL EPIGENETICS DIAGNOSTIC MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 156 ISRAEL EPIGENETICS DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 157 REST OF MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTICS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET
FIGURE 15 EPIGENETIC REGULATION IN CANCER
FIGURE 16 PREVALENCE OF CANCER WORLDWIDE
FIGURE 17 ESTIMATED AGE-STANDARDIZED INCIDENCE RATES WORLDWIDE
FIGURE 18 NORTH AMERICA AGING POPULATION (IN MILLIONS)
FIGURE 19 GERIATRIC POPULATION WORLWIDE
FIGURE 20 NCI FUNDING FOR CANCER RESEARCH
FIGURE 21 EPIGENETIC IVD TESTS
FIGURE 22 THREE NEXT GENERATION SEQUENCING PLATFORMS
FIGURE 23 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2020
FIGURE 24 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2020
FIGURE 28 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, 2021-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2020
FIGURE 32 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, 2021-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY TYPE OF THERAPY, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2020
FIGURE 36 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2020
FIGURE 40 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 44 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 45 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 46 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: SNAPSHOT (2020)
FIGURE 48 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020)
FIGURE 49 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2028)
FIGURE 50 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY COUNTRY (2020 & 2028)
FIGURE 51 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: BY PRODUCT (2021-2028)
FIGURE 52 MIDDLE EAST & AFRICA EPIGENETICS DIAGNOSTIC MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
